Physician profile
Peter I Yi
NPI 1457499618
$371.99
in general payments reported to CMS, 2019-2025
9 companies · $264 in 2025
The $264 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13.04 · 2021: $11.92 · 2022: $14.52 · 2023: $19.81 · 2024: $48.94 · 2025: $264.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $313 · Education: $19.81.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $312.70 |
| Education | $19.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $76.26 | 2025 | |
| Telix Pharmaceuticals | $73.93 | 2025 | Illuccix |
| Janssen Biotech, INC. | $73.65 | 2022-2025 | Tecvayli, Talvey, Darzalex |
| Tempus Ai, INC | $38.40 | 2025 | Xt Cdx |
| Incyte Corporation | $35.82 | 2025 | Jakafi |
| Janssen Pharmaceuticals, INC | $29.16 | 2024 | Xarelto |
| Merck Sharp & Dohme LLC | $19.81 | 2023 | Keytruda |
| Pfizer INC. | $13.04 | 2019 | |
| Gilead Sciences, INC. | $11.92 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Yi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.